Clipping of news on Brazilian Culture, Law and Citizenship
09/26/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
transparent image
Fernanda Cruz
Brazil Agency reporter
São Paulo - The Butantan Institute , in partnership with the University of São Paulo ( USP ) , starts in October tests in humans for a vaccine against dengue . The vaccine is being developed to combat , in a single dose , four types of disease have been identified worldwide. According to Alexander Precious , director of Clinical Trials of Butantan , no other country has such a vaccine .
The vaccine was first developed in 2006 , along with the National Institutes of Health in the United States . Viruses were identified in the North American country and subsequently transferred to the Butantã in 2010 .
The technique uses the so-called attenuated . " This ignifica the dengue virus itself is changed to be able to make people produce antibodies but without developing the disease ," said Precious.
Scientists have tested the vaccine in more than 600 Americans . " Studies have shown that there is a safe vaccine and was able to make people produce antibodies cons four viruses ," he said . The researcher also explained that these volunteers , no significant side effects were observed , only pain and redness at the injection site , feeling common to vaccines .
However , as the United States is not a region endemic for dengue , any volunteer who received immunization had contracted the disease before . In Brazil , the tests will also involve people who have had dengue.
The scientist said that, based on published studies in Southeast Asia and the United States , patients with a history of dengue immunization may receive no health risk . " Early in the development of the vaccine there [ in the U.S. ] , some people received monovalent , only one type , and then another shot of a different virus to see if anyone had the past would be at risk of dengue ," he explained .
In the first stage of the Brazilian tests , which begin this week , 50 volunteers will be recruited from the state capital , and all healthy adults who never had dengue , aged between 18 and 59 years , of both sexes . They will be immunized in two doses with an interval of six months between them .
The next step will include people with a history of dengue and the vaccine will be given in a single dose . 250 volunteers will be the capital city and the city of Ribeirão Preto, in the state .
" We work with the hypothesis that it [ the vaccine ] will be worked in one dose, but in the first 50 volunteers will be two doses ," said Precious. " Results there [ the United States ] have shown that the vaccine already operates with only one dose . How it will be the first time used in a dengue endemic region , we evaluate the two schemes [ one or two doses ] and two types of people [ have had or never had dengue ] , "he added .
The third and final phase will recruit people from different parts of the country , of various ages . " It will generate the result that we need to apply for registration with ANVISA and , from there , the vaccine will be available ." The prediction of the researchers is that the vaccine reaches the population in five years.
Edition : Grace Adjuto
All content on this website is published under the Creative Commons Attribution 3.0 Brazil . To reproduce the material is only required to credit the Agency Brazil
Source : Agencia Brazil
Our news are taken in full from our partner sites . For this reason , we can not change the contents of the same even in cases of typos .
This article was translated by an automatic translation system, and was therefore not reviewed by people.